Guided Therapeutics (GTHP) Cash from Financing Activities (2011 - 2026)
Guided Therapeutics (GTHP) posted Cash from Financing Activities of $267000.0 for Q4 2025, up 47.51% sequentially from $181000.0 in Q3 2025, and down 49.24% YoY from $526000.0 in Q4 2024.
Guided Therapeutics (GTHP) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Guided Therapeutics has reported Cash from Financing Activities for 15 years, with the latest figure at $267000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 49.24% year-over-year to $267000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $745000.0 (down 18.67% YoY) and the FY2025 annual result came in at $745000.0, down 18.67% from the prior year.
- Cash from Financing Activities rose to $267000.0 in Q4 2025 per GTHP's latest filing, from $181000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $2.9 million in Q3 2022 and troughed at -$154000.0 in Q3 2023.
- A 5-year average of $346600.0 and a median of $188500.0 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities surged 687.88% in 2022, then plunged 300.0% in 2024.
- Over 5 years, Cash from Financing Activities stood at -$53000.0 in 2021, then climbed by 20.75% to -$42000.0 in 2022, then surged by 566.67% to $196000.0 in 2023, then jumped by 168.37% to $526000.0 in 2024, then plunged by 49.24% to $267000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $267000.0, $181000.0, and $239000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -213.50 Mn |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | -38,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38,000.00 |
| Jun 30, 2026 | -38,000.00 |
| Mar 31, 2026 | 923,000.00 |
| Mar 31, 2026 | 923,000.00 |
| Dec 31, 2025 | 267,000.00 |
| Dec 31, 2025 | 267,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Sep 30, 2025 | 181,000.00 |
| Jun 30, 2025 | 239,000.00 |
| Jun 30, 2025 | 239,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | 526,000.00 |
| Dec 31, 2024 | 526,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Mar 31, 2024 | -46,000.00 |